Market Overview

UPDATE: MLV & Co Initiates Coverage On Rexahn Pharmaceuticals On Oncology Pipeline With Strategic Flexibility


In a report published Friday, MLV & Co analyst Vernon T. Bernardino initiated coverage on Rexahn Pharmaceuticals, Inc. (NYSE: RNN) with a Buy rating and $1.25 price target.

In the report, MLV & Co noted, "We initiate coverage of Rexahn Pharmaceuticals Inc. (RNN) with a BUY rating and $1.25 PT. We believe investors undervalue Rexahn's clinical-stage oncology assets, which have demonstrated activity in multiple tumor types. We anticipate Rexahn will out-license commercialization of each asset in 1-2 types of cancer, with revenue streams from each worth $0.10- $0.25/sh, and upside potential with advancement in at least 1-2 other cancers ($0.10-$0.50/sh). As a result, we believe the premium valuations ascribed to other oncology-focused companies (EV of $285MM), whose assets we note do not have the broad activity of Rexahn's compounds, should be extended to Rexahn.

"Thus, using DCF analysis, we believe there is upside to $0.91/sh, and by comparable EV analysis, we look for upside to $1.59/sh, which we averaged to $1.25/sh. Lastly, we believe the overhang of a near-term capital raise now passed. With $36MM in cash and our forecast for $34MM in OpEx through 2017, we believe the material risk of shareholder dilution minimal. Therefore, with multiple catalysts anticipated through 2015, we believe current prices offer attractive entry points and would be buyers of the stock."

Rexahn Pharmaceuticals closed on Thursday at $0.70.

Latest Ratings for RNN

Jul 2018Initiates Coverage OnBuy
Oct 2017Initiates Coverage OnBuy
Apr 2017Initiates Coverage OnBuy

View More Analyst Ratings for RNN
View the Latest Analyst Ratings

Posted-In: MLV & Co Vernon T. BernardinoAnalyst Color Initiation Analyst Ratings


Related Articles (RNN)

View Comments and Join the Discussion!

Latest Ratings

WENMorgan StanleyMaintains22.0
XGNCantor FitzgeraldInitiates Coverage On18.0
LOOPRoth CapitalInitiates Coverage On14.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

3 Retailers Wolfe Research Likes (And 2 It Doesn't)

Here's What The Street's Saying About Lennar